Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: Doxycycline Supply Remains Sparse, FDA Warns


PhysBizTech (02.05.13)

Following the US Food and Drug Administration’s (FDA’s) official announcement on January 18 of a doxycycline shortage, quantities of the drug remain in short supply. The decreased availability is due in part to both manufacturing delays and use of the drug as a primary treatment for many sexually transmitted diseases such as chlamydia, nongonococcal urethritis, epididymitis, and pelvic inflammatory disease. CDC has provided a series of alternative treatment options for physicians to consider for their patients at FDA has listed additional information on manufacturer status regarding the antibiotic, contact information, and other commentary at


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in February 6, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.